%0 Journal Article
%T Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation
%A Trina Das
%A Deborah L. Diamond
%A Matthew Yeh
%A Sajida Hassan
%A Janine T. Bryan
%A Jorge D. Reyes
%A James D. Perkins
%J Journal of Transplantation
%D 2013
%I Hindawi Publishing Corporation
%R 10.1155/2013/878297
%X Chronic hepatitis C virus (HCV) induced hepatocellular carcinoma (HCC) is a primary indication for liver transplantation (LT). In western countries, the estimated rate of HCC recurrence following LT is between 15% and 20% and is a major cause of mortality. Currently, there is no standard method to treat patients who are at high risk for HCC recurrence. The aim of this study was to investigate the molecular signatures underlying HCC recurrence that may lead to future studies on gene regulation contributing to new therapeutic options. Two groups of patients were selected, one including patients with HCV who developed HCC recurrence (HCC-R) ¡Ü3 years from LT and the second group including patients with HCV who did not have recurrent HCC (HCC-NR). Microarray analysis containing more than 29,000 known genes was performed on formalin-fixed-paraffin-embedded (FFPE) liver tissue from explanted livers. Gene expression profiling revealed 194 differentially regulated genes between the two groups. These genes belonged to cellular networks including cell cycle G1/S checkpoint regulators, RAN signaling, chronic myeloid leukemia signaling, molecular mechanisms of cancer, FXR/RXR activation and hepatic cholestasis. A subset of molecular signatures associated with HCC recurrence was found. The expression levels of these genes were validated by quantitative PCR analysis. 1. Introduction Hepatitis C virus (HCV) infection is the most common cause of hepatocellular carcinoma (HCC) in the USA, Europe, and Japan, accounting for 47%¨C49%, 56%, and 75% of cases, respectively [1, 2]. HCC causes >600,000 deaths annually worldwide and is the most common primary liver cancer [3]. Definitive treatment for HCC is surgical resection when possible or liver transplantation for patients with end-stage liver disease and liver tumors. In USA, transplant guidelines stipulate that eligibility for liver transplantation is determined by the patient¡¯s liver tumor(s) meeting the Milan criteria (a single tumor ¡Ü5£¿cm in diameter or up to 3 tumors with individual diameters ¡Ü3£¿cm and no macrovascular invasion) [4]. Unfortunately, the recurrence of HCC is a major cause of mortality in surgically treated patients [5]. There is no standard therapy for patients who are at high risk for HCC recurrence. Hence, a better understanding of the molecular mechanisms involved in the recurrence of HCC post LT is necessary to develop an efficient surveillance protocol and seek new potential therapies. Gene expression profiling is best performed on fresh or frozen tissue to lessen the degradation of RNA. However,
%U http://www.hindawi.com/journals/jtrans/2013/878297/